Currently, there are 45.68M common shares owned by the public and among those 40.15M shares have been available to trade.
The company’s stock has a 5-day price change of -25.28% and -30.35% over the past three months. CAPR shares are trading 94.33% year to date (YTD), with the 12-month market performance down to -32.97% lower. It has a 12-month low price of $3.52 and touched a high of $23.40 over the same period. CAPR has an average intraday trading volume of 2.44 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -19.58%, -14.34%, and -31.04% respectively.
Institutional ownership of Capricor Therapeutics Inc (NASDAQ: CAPR) shares accounts for 40.49% of the company’s 45.68M shares outstanding.
It has a market capitalization of $422.80M and a beta (3y monthly) value of 0.83. The earnings-per-share (ttm) stands at -$1.42. Price movements for the stock have been influenced by the stock’s volatility, which stands at 22.88% over the week and 11.51% over the month.
Earnings per share for the fiscal year are expected to increase by 81.09%, and -155.75% over the next financial year.
Looking at the support for the CAPR, a number of firms have released research notes about the stock. Roth Capital stated their Buy rating for the stock in a research note on May 20, 2025, with the firm’s price target at $31. Piper Sandler coverage for the Capricor Therapeutics Inc (CAPR) stock in a research note released on October 21, 2024 offered a Overweight rating with a price target of $35. Oppenheimer was of a view on May 17, 2024 that the stock is Outperform, while Cantor Fitzgerald gave the stock Overweight rating on January 05, 2024, issuing a price target of $8. Ladenburg Thalmann on their part issued Buy rating on October 26, 2022.
